Health and Healthcare
What's Next for Durect After FDA Posimir Vote
Published:
Last Updated:
Durect Corp. (NASDAQ: DRRX) shares dropped early on Friday after the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) announced its vote on Posimir, the company’s pain relief treatment. Ultimately, the vote did not go as Durect investors hoped. However, this FDA move was similar to an AADPAC vote we saw earlier this week for Nektar Therapeutics,
The FDA’s AADPAC met Thursday to discuss the Class 2 New Drug Application (NDA) resubmission for Posimir (bupivacaine extended-release solution). In a split vote on the key question, six advisory committee members voted to recommend that the efficacy, safety and overall risk-benefit profile of Posimir support approval, while six did not support approval, based on the information presented.
Although the FDA considers the recommendations of the AADPAC, the recommendations by the panel are non-binding. The final decision regarding pending regulatory actions for a product is made by the FDA.
James E. Brown, president and CEO of Durect, commented:
We appreciated this opportunity to present an in depth overview of our Posimir data and discuss it with the committee. We are encouraged by the support from a number of the Committee members. We continue to believe the data meets all of the regulatory requirements and that the weight of the evidence supports approval. We look forward to working with the agency as it completes its review of the POSIMIR application.
Some background: Posimir is the company’s investigational post-operative pain relief depot product that utilizes Durect’s patented Saber technology. Posimir is designed to be administered directly into the surgical site to deliver bupivacaine for up to three days after surgery.
Durect stock traded down more than 11% early Thursday at $2.25 a share, in a 52-week range of $0.50 to $3.95. The consensus price target is $4.20.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
